EN DE

Sofwave Medical Ltd (SOFW) Fair Value & Analysis

Healthcare · Il · Market cap 1.2B ILA · ISIN IL0011754392

SM Sofwave Medical Ltd SOFW · TA
Price37.20 ILA
Fair Value9.08 ILA
Upside-75.6%
Quality75/100
Watch Sofwave Medical Ltd for free, get notified when fair value or trend changes. Watch for free

Strengths

✓Healthy Growth (revenue 5y +85.7 %/yr)
✓generates free cash flow

Risks

!Trades 310% ABOVE our fair value of 9.08 ILA
!Thin margins · 8.2% net margin
!Mixed vs. peers (6/12)
!Moderate moat 62/100
Healthy Growth (revenue 5y +85.7 %/yr)
Thin margins · 8.2% net margin
generates free cash flow
Mixed vs. peers (6/12)
Moderate moat 62/100
Evidence: High Range 6.81 ILA – 11.35 ILA Share as image

Fair value as of: Aug 27, 2026

From 24 valuation models · updated yesterday

Share price −5.7% over the past month.

A strong business, but trading 310% above our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Track Sofwave Medical Ltd and get told automatically when its fair value or trend turns, plus fair value for all 35,000+ stocks. 14 days of Pro free, no card. Track it free

What matters now

  • A high-quality business (quality 75/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
  • The price sits above even our optimistic bull case (11.35 ILA). The favourable scenario is already priced in.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

47.44 ILA 7.01 ILA Fair Value 9.08 ILA May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.

How to read this chart

60‑month range 7.01 ILA – 47.44 ILA · fair‑value band 6.81 ILA – 11.35 ILA · the 37.20 ILA price screens above the 9.08 ILA fair value. Dashed = 300-day average. As of Aug 27, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Sofwave Medical Ltd (SOFW) currently trades at 37.20 ILA, while our model-based Fair Value estimate is 9.08 ILA, implying the stock looks roughly 75.6% overvalued today. The Quality Score stands at 75/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Sofwave Medical Ltd generated revenue of 95.4M ILA at a net margin of 8.2%. Revenue grew 46.4% year over year. It earns a return on equity of 26.5%. The balance sheet holds a net cash position of 33.6M ILA. Fundamentals as of Aug 27, 2026

Our scenario range runs from 6.81 ILA (bear case) to 11.35 ILA (bull case); at 37.20 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at -76%, SOFW screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (0.6000 ILA to 9.77 ILA). Read the values as a conservative anchor, not as a price target.
Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 6.05 ILA 9.77 ILA 15.60 ILA 72
Growth-Adj P/E 5.32 ILA 7.60 ILA 9.88 ILA 68
Rev-Margin DCF 4.37 ILA 6.50 ILA 10.98 ILA 67
All 24 models by family
DCF Models
FCF DCF 6.40 ILA 8.90 ILA 16.37 ILA 38
Owner Earnings 3.53 ILA 6.28 ILA 11.40 ILA 31
5Y Revenue Exit 4.08 ILA 5.80 ILA 9.33 ILA 39
5Y EBITDA Exit 4.58 ILA 6.80 ILA 11.13 ILA 41
5Y P/E Exit 4.57 ILA 8.12 ILA 12.81 ILA 38
10Y Revenue Exit 4.81 ILA 8.06 ILA 9.73 ILA 36
10Y EBITDA Exit 5.21 ILA 9.04 ILA 15.27 ILA 37
10Y P/E Exit 5.21 ILA 9.01 ILA 14.92 ILA 35
Earnings-Based
Graham-Dodd 1.11 ILA 7.76 ILA 10.89 ILA 54
Lynch FV 4.01 ILA 5.73 ILA 7.45 ILA 50
PEG = 1.0 4.01 ILA 5.73 ILA 7.45 ILA 46
EPV 2.43 ILA 2.63 ILA 2.80 ILA 59
Multiples
P/E Multiple 2.70 ILA 3.60 ILA 4.50 ILA 63
P/S Multiple 2.09 ILA 2.78 ILA 3.48 ILA 58
P/B Multiple 2.09 ILA 2.78 ILA 3.48 ILA 55
EV/EBIT 3.57 ILA 4.44 ILA 5.31 ILA 53
EV/EBITDA 3.67 ILA 4.58 ILA 5.49 ILA 54
EV/Revenue 2.82 ILA 3.62 ILA 4.42 ILA 43
Asset-Based
NCAV (Graham) 0.4500 ILA 0.6000 ILA 0.9000 ILA 50
Growth DCF
Growth DCF 6.05 ILA 9.77 ILA 15.60 ILA 72
Rev-Margin DCF 4.37 ILA 6.50 ILA 10.98 ILA 67
Economic Profit
Residual Income 0.9300 ILA 1.24 ILA 3.59 ILA 61
ROIC Compounder 2.43 ILA 2.63 ILA 2.80 ILA 67
Growth Earnings
Growth-Adj P/E 5.32 ILA 7.60 ILA 9.88 ILA 68

Widest divergence: DCF Models (8.06 ILA) versus Asset-Based (0.6000 ILA). Highest evidence: Growth DCF (72).

Notify me when SOFW reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 64.1
P/S ratio 4.02 P/E × margin
EPS (TTM) 0.5800 ILA price ÷ EPS = P/E 64.1
Net margin 6.3% FY2025
Return on equity 26.5% TTM
Return on assets (EBIT) -13.1% avg 5y
More key figures
Profitability
Operating margin 6.7% TTM
Growth
Revenue (TTM) 95.4M ILA TTM
Revenue growth (YoY) +46.4% 3y avg +38.6%
Balance sheet & cash flow
Free cash flow 14.5M ILA FY2025
Net cash 33.6M ILA FY2025

Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 75/100

Of which business quality 75 · Market factors (momentum, volatility) 58

Profitability 74
Margins and returns on capital today
Quality Growth 86
Are margins and returns improving?
Cashflow 82
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 65
Calm price path (market factor)
Momentum 52
Price trend over the last 3–12 months (market factor)
52W Momentum 63
Distance to the 52-week high (market factor)
Net Issuance 14
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally.

Full company description

SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-invasive muscle toning technology under the Pure Impact VIP brand. It serves plastic surgeons, dermatologists, and other physicians who perform aesthetic treatments on patients. It also provides technical and clinical product support services. The company was incorporated in 2015 and is based in Yokneam Illit, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Sofwave Medical Ltd reported revenue of $94.9M in FY2025 versus $21.8M in FY2021, a compound +44.4%/yr. Reported net income was $5.9M in FY2025.

Growth Quality 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
94.9M ILS
Latest YoY
+59.0%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+38.6%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+85.7%
Avg. revenue growth/yr (6Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+164.3%
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Revenue +44.4%/yr
FY21 $21.8M
FY22 $35.6M
FY23 $50.3M
FY24 $59.7M
FY25 $94.9M
Net income
FY21 −$6.8M
FY22 −$19.5M
FY23 −$8.3M
FY24 −$4.5M
FY25 $5.9M

SOFW screens 76% overvalued. Compare with Abbott Laboratories, →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sofwave Medical Ltd · Fair Value
9.08 ILA −76%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sofwave Medical Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SOFW

Peer Group

Medical Devices · 364 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 75 · Top 25%
Fair Value upside −76% · Bottom 25%
Return on equity (TTM) 27% · Top 25%
Return on assets 12% · Top 25%
Net margin (TTM) 8% · Above median
Operating margin (TTM) 7% · Above median
Revenue growth 46% · Top 25%

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 64.1× · Pricier than 75% of peers
P/B 12.82× · Pricier than 75% of peers
P/S (TTM) 4.40× · Pricier than 75% of peers
P/FCF 28.9× · Pricier than 75% of peers
EV/EBITDA 36.2× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 32
PAST100 · sector 5
HEALTH0 · sector 97
DIVIDEND0 · sector 33

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $114.10 $74.79 -34%
Stryker Corporation SYK $329.67 $186.28 -43%
Medtronic plc MDT $92.02 $65.57 -29%
Boston Scientific Corporation BSX $48.17 $30.73 -36%
Edwards Lifesciences Corporation EW $90.78 $41.02 -55%
Siemens Healthineers AG SHL €39.26 €33.87 -14%
DexCom, Inc DXCM $88.96 $38.95 -56%
GE HealthCare Technologies Inc GEHC $74.82 $64.13 -14%
Koninklijke Philips N.V PHIA €23.69 €14.36 -39%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥150.63 ¥147.63 -2%

Compare Sofwave Medical Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Sofwave Medical Ltd (SOFW) overvalued or undervalued?
As of Aug 27, 2026, our model estimates a fair value of 9.08 ILA versus a price of 37.20 ILA, about −76% (overvalued).
What is the fair value of SOFW?
Our model-based fair value for Sofwave Medical Ltd is 9.08 ILA (as of Aug 27, 2026), built from audited fundamentals. The current price: 37.20 ILA.
What is the quality score of SOFW?
Sofwave Medical Ltd has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Sofwave Medical Ltd (SOFW)?
Sofwave Medical Ltd reported trailing-twelve-month revenue of about 95.4M ILS (latest available figure, as of Aug 27, 2026).
What is the net profit margin of SOFW?
The net profit margin of Sofwave Medical Ltd is about 8.2%, meaning it keeps roughly 8.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free · no account needed

Watch Sofwave Medical Ltd in the live analysis

One click puts Sofwave Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.